| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42001359 | EBV | ENSG00000050628.21 | protein_coding | PTGER3 | No | No | 5733 | O00325 P43115 |
| TVIS30011273 | HIV | ENSG00000050628.21 | protein_coding | PTGER3 | No | No | 5733 | O00325 P43115 |
| TVIS30005264 | HIV | ENSG00000050628.21 | protein_coding | PTGER3 | No | No | 5733 | O00325 P43115 |
| TVIS30084972 | HIV | ENSG00000050628.21 | protein_coding | PTGER3 | No | No | 5733 | O00325 P43115 |
| TVIS30083069 | HIV | ENSG00000050628.21 | protein_coding | PTGER3 | No | No | 5733 | O00325 P43115 |
| TVIS30024050 | HIV | ENSG00000050628.21 | protein_coding | PTGER3 | No | No | 5733 | O00325 P43115 |
| TVIS30024051 | HIV | ENSG00000050628.21 | protein_coding | PTGER3 | No | No | 5733 | O00325 P43115 |
| TVIS30024052 | HIV | ENSG00000050628.21 | protein_coding | PTGER3 | No | No | 5733 | O00325 P43115 |
| TVIS30024053 | HIV | ENSG00000050628.21 | protein_coding | PTGER3 | No | No | 5733 | O00325 P43115 |
| TVIS30024054 | HIV | ENSG00000050628.21 | protein_coding | PTGER3 | No | No | 5733 | O00325 P43115 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PTGER3 |
|---|---|
| DrugBank ID | DB00917 |
| Drug Name | Dinoprostone |
| Target ID | BE0002375 |
| UniProt ID | P43115 |
| Regulation Type | agonist |
| PubMed IDs | 18715952; 20599704; 19788928; 17329241 |
| Citations | Baryawno N, Sveinbjornsson B, Eksborg S, Orrego A, Segerstrom L, Oqvist CO, Holm S, Gustavsson B, Kagedal B, Kogner P, Johnsen JI: Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol. 2008 Oct;10(5):661-74. doi: 10.1215/15228517-2008-035. Epub 2008 Aug 20.@@Tamiji J, Crawford DA: Prostaglandin E(2) and misoprostol induce neurite retraction in Neuro-2a cells. Biochem Biophys Res Commun. 2010 Jul 30;398(3):450-6. doi: 10.1016/j.bbrc.2010.06.098. Epub 2010 Jun 27.@@Legler DF, Bruckner M, Uetz-von Allmen E, Krause P: Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol. 2010 Feb;42(2):198-201. doi: 10.1016/j.biocel.2009.09.015. Epub 2009 Sep 27.@@Sugimoto Y, Narumiya S: Prostaglandin E receptors. J Biol Chem. 2007 Apr 20;282(16):11613-7. Epub 2007 Feb 28. |
| Groups | Approved |
| Direct Classification | Prostaglandins and related compounds |
| SMILES | CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CC=C/CCCC(O)=O |
| Pathways | Arachidonic Acid Metabolism; Flurbiprofen Action Pathway; Oxaprozin Action Pathway; Rofecoxib Action Pathway; Mefenamic Acid Action Pathway; Bromfenac Action Pathway; Naproxen Action Pathway; Ketoprofen Action Pathway; Sulindac Action Pathway; Piroxicam Action Pathway; Phenylbutazone Action Pathway; Nabumetone Action Pathway; Salicylate-Sodium Action Pathway; Acetaminophen Action Pathway; Etoricoxib Action Pathway; Meloxicam Action Pathway; Celecoxib Action Pathway; Lumiracoxib Action Pathway; Suprofen Action Pathway; Indomethacin Action Pathway; Valdecoxib Action Pathway; Ketorolac Action Pathway; Acetylsalicylic Acid Action Pathway; Antipyrine Action Pathway; Carprofen Action Pathway; Ibuprofen Action Pathway; Diclofenac Action Pathway; Nepafenac Action Pathway; Salsalate Action Pathway; Etodolac Action Pathway |
| PharmGKB | PA449345 |
| ChEMBL | CHEMBL548 |
